Source:European Journal of Surgical Oncology (EJSO)
Author(s): Yeqian Huang, Nayef A. Alzahrani, Winston Liauw, Hussein Soudy, Abdulaziz M. Alzahrani, David L. Morris
IntroductionThe combined approach of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved encouraging outcomes for patients with PMCA with peritoneal dissemination. However, there is little evidence for the use of EPIC in addition to HIPEC in this group of patients.Patients and MethodsThis was a retrospective study of prospectively collected data of consecutive patients with PMCA who underwent CRS and perioperative intraperitoneal chemotherapy by one surgical team at St George Hospital in Sydney, Australia between Jan 1996 and Aug 2016.ResultsA total of 185 patients formed the cohort of this study. However, there was no significant difference in terms of hospital mortality (p=0.632), major morbidity rate (i.e. Grade III/IV) (p=0.444), intensive unit care stay (p=0.638) and total hospital stay (p=0.0.078). However, patients who received HIPEC and EPIC had a significant longer stay in high dependency unit (p<0.001). Multivariate analysis showed combined HIPEC with EPIC is an independent prognostic factor for better overall survival (Hazard ratio (HR)=0.42, 95% confidence interval (CI)=0.19-0.92, P=0.030) and disease free survival (HR=0.66, 95%CI=0.44-0.99, p=0.045), adjusted for age, sex, peritoneal cancer index, completeness of cytoreduction score, CEA≥6.5mg/L, CA19-9≥24.0 U/mL and CA125≥32.0 U/mL.ConclusionsIn summary, the combination of HIPEC and EPIC could potentially provide additional survival benefit for patients with PMCA with peritoneal spread as compared to HIPEC alone without increasing postoperative morbidity and mortality. More studies are warranted to further confirm the potential benefits of EPIC in PMCA and address the question of optimal drug and/or duration of EPIC.
http://ift.tt/2ykFCDi
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου